National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Brentuximab vedotin (Adcetris®) indicated for the treatment of adult patients with relapsed or refractory CD30 positive Hodgkin lymphoma following autologous stem cell transplant  or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option and is also indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma.

Rapid Review

Commenced Completed Outcome
28/11/2012 21/12/2012 Full Pharmacoeconomic Assessment Recommended

Pharmoeconomic Evaluation

Commenced Completed Outcome
16/09/2013  11/04/2014 Reimbursement not Recommended

Summary

December 2015

The HSE has approved reimbursement following confidential price negotiations.